Skip to content

Microdosing research published in 2023

Page 2 of 2: studies 21 to 28 of 28, newest first. Back to the microdosing overview

Studies

Feasibility of implantable microdosing devices to perform in vivo pharmacotyping in pancreatic cancer.

Journal of Clinical Oncology February 1, 2023 Lyudmyla Demyan, Oliver Standring, Taemoon Chung et al.

742 Background: Current biomarkers offer modest predictive capacity for drug sensitivity testing in pancreatic cancer. Patient-specific pharmacotyping offers the potential for a more direct, personalized prediction model. Recently, an implantable microdevice was developed to facilitate in situ multi-agent pharmacotyping and has since entered clinical trials in multiple cancer types, but had not...

Microdosing Sprint Distribution as an Alternative to Achieve Better Sprint Performance in Field Hockey Players

Sensors January 20, 2023 Víctor Cuadrado-Peñafiel, Adrián Castaño-Zambudio, Luis Manuel Martínez-Aranda et al.

Introduction: The implementation of optimal sprint training volume is a relevant component of team sport performance. This study aimed to compare the efficiency and effectiveness of two different configurations of within-season training load distribution on sprint performance over 6 weeks. Methods: Twenty male professional FH players participated in the study. Players were conveniently assigned...

Microdosing psychedelics – Does it have an impact on emodiversity?

Journal of Psychedelic Studies January 17, 2023 Ioana Pop, Jannis Dinkelacker 4 citations

Abstract Background and aims Previous research has proposed that microdosing, i.e., the repeated use of sub-threshold doses of serotonergic hallucinogens, has an impact on mood by increasing emotional awareness. We propose that increased emotional awareness could translate into higher emodiversity, a balanced experience of emotions in which emotions are experienced with more similarity in...

DOI: 10.1556/2054.2022.00208 (opens in new tab) Full text (opens in new tab) Mood Affect linguistics Test biology Communication

Legal Limitations Associated with Microdosing Buprenorphine.

Substance Use & Misuse 2023 Barbara Andraka-Christou, Matthew Douglas Evans, Beth Tranen et al.

Background: Opioid overdose deaths in the U.S. continue to increase, largely due to the prevalence of fentanyl, a very powerful opioid, in the illicit drug supply. Buprenorphine treatment is effective for treating opioid use disorder, but it can be challenging for clinicians to introduce buprenorphine treatment to people who use fentanyl due to risks of precipitated withdrawal. Induction could...

Yield response of African leafy vegetables to combined manure and urea microdosing in West Africa

Base 2023 André Adjogboto, Dagnon Didier Likpètè, C. Sossa-Vihotogbe et al.

Description of the subject. Fertilizers microdosing was tested for African leafy vegetables (ALVs) production to reduce the high rates of fertilizers usually applied to their production in West Africa. Objectives. This study aims to (i) evaluate the response of three ALVs (Amaranthus cruentus L., Solanum macrocarpon L. and Ocimum gratissimum L.) to cattle manure combined with urea-N microdosing...

Carbon‐13 labeling of ibrutinib for human microdosing

Journal of Labelled Compounds and Radiopharmaceuticals 2023 Yong Gong, Rhys Salter

Ibrutinib is an oral medication for the treatment of B cell malignancies. During its clinical development, a stable isotopologue of ibrutinib was required for the assessment of the drug's absolute oral bioavailability via intravenous microdosing. The following work describes a 10‐step, gram‐scale production of carbon‐13 labeled ibrutinib from [13C6]phenol (13C6, 99%) in 31% overall yield with...

Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.

Neuropsychopharmacology 2023 James Glazer, Conor H. Murray, Robin Nusslock et al. 52 citations

Renewed interest in classic psychedelics as treatments for psychiatric disorders warrants a deeper understanding of their neural mechanisms. Single, high doses of psychedelic drugs have shown promise in treating depressive disorders, perhaps by reversing deficits in reward processing in the brain. In addition, there are anecdotal reports that repeated ingestion of low doses of LSD, or...